

Message from the management

On 100-year route

In 2024, we achieved leadership regarding sales in Latin America in the pharmaceutical segment. The achievement anticipates one of the major ambitions described in the group's vision 2027 and reinforces the discipline in executing the strategic plan that defines the company's main guidelines to more than 13,300 employees in the 24 countries where we operate.

With R\$ 11 billion net revenue, we grew by 20% over 2023 and our adjusted EBITDA was R\$ 2.5 billion in the same period. Most of our growth - 15% - resulted organically and 5% from the acquisition of Genfar.

EBITDA did not grow in the same proportion of the sales, because, in addition to increased investment in Innovation, other important growth levers that reflect our belief in the future, such as the expansion of the sales force, are allocated to expense lines.

Our recent investments are generating the expected return and are important drivers for maintaining our growth levels, of around 17% per year, during the last 15 years. The Genfar operation, our global generics brand, is fully integrated and we have an expansion plan underway to take it to all the countries where we operate. We repositioned the Valda brand, which together with the OAZ line, are the pillars of our new OTC division, until recently an almost unknown market for us.

The facility under construction in the city of Montes Claros, designed to be one of the largest in the world, will start-up part of the activities in 2025. And the 25% increase in the sales force, accomplished in 2022, is already showing results reflected by internal growth and an increase in market share in the main segments in which we operate.

Even with all those investments, our net debt continues to fall, complying with all the covenants, with an AAA rating. With only 40 days' worth of stock at major distributors and account receivable of 60 days, we certainly maintain one of the healthiest financial cycles in the market. Regarding our workforce, our greatest asset, we continue to follow best practices and have been recognized by Great Place to Work, both in Brazil and in many of the other countries in which we operate, ranking as one of the best companies to work for over the last 20 consecutive years. Over 92% of our employees are proud to work for us and our voluntary turnover rate is less than 2%. In addition, 70% of our new leadership positions are occupied internally by our people.

Our investment in innovation totaled more than R\$ 800 million, an increase of 25% over the foregoing year. The Company currently has more than 400 projects in the pipeline, both generic and incremental. In radical innovation, we have

two projects that could soon enter phase 1. All of them are conducted by a team of more than 750 professionals. Eurofarma Ventures, our biotechnology corporate venture capital fund, has investments in two funds and seven companies and includes radical innovation projects with ongoing clinical trials.

Pioneers in sustainability, our social investments totaled R\$ 165 million, 54% over the previous year. Our private breast milk bank, Lactare, has now completed five years being already the largest in Brazil, having supported over 2,000 premature babies in 10 public hospitals. At Instituto Eurofarma, we benefited more than 21 thousand young people in 2024 with our educational projects. We donated 1.7 million units of medicine and 200,000 basic food baskets to the neediest.

In the environmental dimension, we have increased the share of renewable energy sources in our energy matrix by almost 200%, reached the mark of 90% use of clean energy, and neutralized 85% of direct carbon emissions.

In keeping with the values and teachings of our founder's enterprising spirit, we continue to expand our operations into new geographies, segments, and businesses, always linked to health. Our deliveries and daily efforts are the steps we take towards a future that inspires us

to become one of the world's largest pharmaceutical companies by 2072, when we will be 100 years old.

Despite the macroeconomic challenges facing the region in which we operate, we remain confident in our ability to go further, with ethics, discipline, humility, and determination to achieve our goals. Always together with a team that shares the nonconformity typical of entrepreneurs, we seek the perpetuation of our business and a better future for society, our employees, partners, and other stakeholders. We sincerely thank everyone who is with us.

Maurizio Billi
Chairman



Most innovative pharmaceutical company
VALOR INOVAÇÃO 2024

INTEGRATION OF GENFAR AND EXPANSION of the brand to Central America

Board of Directors with independent members

Global Compliance structure

RATING AAA by Fitch Ratings

R\$ 43.2 MILLION invested in own social programs

R\$ 77.5 MILLION invested in humanitarian aid

13TH BEST COMPANY to work in Brazil in the general ranking and **2ND best pharmaceutical** by GPTW

R\$ 3.6 MILLION invested in brain neuromonitoring program for babies in ICUs


200 THOUSAND basic food baskets donated

1.7 MILLION units of medicines donated to people in situations of social vulnerability

Age Friendly Employer Certification

Executive bonuses linked to diversity objectives


Learn more about Eurofarma:





LEADERSHIP IN PHARMACIES IN LATIN AMERICA AND MARKET SHARE GAINS THROUGHOUT THE REGION

WORKING IN ALL THE MAIN PHARMACEUTICAL SEGMENTS



VISION 2027

In line with Vision 2027, we focus on our routine and plans in 5 different dimensions and 15 major strategic objectives that guide the organization globally.

People and Culture

Result

Innovation

ESG

Internationalization

Operating in the healthcare sector with a global reach, we will become one of the largest pharmaceutical companies in the world. Recognized for our ESG practices, we will be among the most sought companies to work for. True to our purpose of promoting access to healthcare and quality of life, we will be a lasting company, continuously discovering new treatments and building a legacy of innovation.

ASPIRATION FOR 2027

EUROFARMA GROUP

Founded in 1972, Eurofarma operates in the health sector, producing and marketing products and services to improve people's quality of life. Focused on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology, and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving the main medical specialties.

Leader in medical prescriptions in Brazil, where it holds vice-leadership in generics, Eurofarma operates in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has over 13,300 employees and 11 factories, with total production of 600 million units in 2024. In the same year, it invested more than R\$ 800 million in innovation projects and achieved net revenue of R\$ 11 billion.

FINANCIAL STATEMENTS

BALANCE SHEETS AS AT DECEMBER 31, 2024 AND DECEMBER 31, 2023 (IN THOUSANDS OF R\$)

	Parent Company		Consolidated	
	31/12/2024	31/12/2023	31/12/2024	31/12/2023
Assets				
Current Assets				
Cash and cash equivalents	1,441,504	1,297,420	2,103,232	1,660,644
Accounts receivable from clients	1,379,707	1,293,641	2,398,251	2,015,909
Inventories	1,450,469	1,377,668	2,290,917	2,320,024
Current tax assets	67,966	62,706	139,406	108,880
Taxes recoverable	6,091	194,371	84,054	223,782
Advance for future capital increase	-	7,958	-	9
Non-current assets held for sale	-	-	11,157	-
Other receivables	124,219	53,940	142,609	101,370
Total current assets	4,469,956	4,287,704	7,169,626	6,430,618
Non-Current Assets				
Long-term receivables				
Accounts receivable from clients	4,027	5,428	4,027	5,428
Derivative financial instruments	212,708	-	212,708	-
Advance for future capital increase	17,218	-	9	-
Bonds and securities	22,534	11,462	48,743	40,124
Current tax assets	2,616	3,181	2,617	3,190
Deferred tax asset	29,449	83,342	213,222	236,132
Recoverable taxes and contributions	353,580	-	353,580	-
Judicial deposits	33,199	28,948	46,098	39,146
Other receivable	-	-	9,204	473
Total long-term receivable assets	675,331	132,361	890,208	324,493
Investments	6,319,543	5,441,277	139,901	94,812
Other Investments	-	-	15	-
Property, plant and equipment	2,991,469	2,197,447	3,463,963	2,578,425
Right-of-use of assets	505,719	490,733	716,244	653,362
Intangible assets	1,892,607	1,753,801	5,814,305	5,231,438
Total non-current assets	12,384,669	10,015,619	11,024,636	8,882,530
TOTAL ASSETS	16,854,625	14,303,323	18,194,262	15,313,148

Notes are an integral part of the individual and consolidated financial statements.

	Parent Company		Consolidated	
	31/12/2024	31/12/2023	31/12/2024	31/12/2023
Liabilities				
Current Assets				
Suppliers	666,372	551,194	1,047,145	812,810
Derivative financial instruments	78,717	95,224	78,717	95,224
Loans and financings	354,218	1,582,609	354,218	1,582,609
Debentures	153,684	2,407,908	153,684	2,407,908
Leases payable	-	1,247	-	1,247
Lease liabilities	118,574	89,408	193,218	142,810
Payroll and related charges	320,017	291,179	416,708	395,805
Income tax and social contribution payable	-	-	90,598	37,116
Current tax liabilities	39,503	25,945	60,250	39,464
Employee profit sharing	203,209	128,132	272,343	185,737
Dividends and interest on equity payable	418,189	422,458	452,713	425,365
Advance dividends from subsidiaries	-	201	-	201
Other payable	117,237	92,226	346,180	264,005
Total current liabilities	2,469,720	5,687,731	3,465,774	6,390,301
Non-Current Liabilities				
Derivative financial instruments	-	43,922	-	43,922
Loans and financings	2,836,806	2,355,106	2,836,806	2,355,106
Debentures	6,264,930	1,692,561	6,264,930	1,692,561
Lease liabilities	413,090	421,154	558,959	537,881
Deferred tax liabilities	-	-	10,062	7,579
Provision for contingencies	98,766	57,913	151,940	103,087
Other payables	15,411	11,413	97,622	76,012
Total non-current liabilities	9,629,003	4,582,069	9,920,319	4,816,148
Shareholders' equity				
Equity	1,205,522	1,203,878	1,205,522	1,203,878
Capital reserve	(8,598)	(8,598)	(8,598)	(8,598)
Profit reserve	2,728,367	2,820,623	2,728,367	2,820,623
Currency translation adjustments	830,611	17,620	830,611	17,620
Equity attributable to controlling shareholders	4,755,902	4,033,523	4,755,902	4,033,523
Non-controlling interest	-	-	52,267	73,176
Total shareholders' equity Net	4,755,902	4,033,523	4,808,169	4,106,699
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	16,854,625	14,303,323	18,194,262	15,313,148

INCOME STATEMENTS FOR THE YEARS AS AT DECEMBER 31, 2024, AND 2023 (IN THOUSANDS OF R\$)

	Parent Company		Consolidated	
	31/12/2024	31/12/2023	31/12/2024	31/12/2023
Net revenue	7,320,718	6,588,181	10,973,515	9,120,676
Cost of products sold	(2,552,254)	(2,411,947)	(3,849,753)	(3,076,381)
Gross profit	4,768,464	4,176,234	7,123,762	6,044,295
Selling expenses	(2,613,025)	(2,207,050)	(4,068,399)	(3,264,006)
Administrative expenses	(1,134,907)	(859,385)	(1,732,583)	(1,385,745)
Impairment	(39,974)	(11,619)	(47,256)	(13,625)
on accounts receivables	62,833	64,752	100,412	80,824
Other revenue	(13,001)	(19,309)	(17,491)	(20,737)
Operating profit before net financial result	1,030,390	1,143,623	1,358,445	1,441,006
Financial revenue	516,189	293,834	571,522	344,873
Financial expenses	(1,491,203)	(1,000,742)	(1,603,243)	(1,043,123)
Net financial result	(975,014)	(706,908)	(1,031,721)	(698,250)
Equity in earnings (losses)	76,885	164,368	(445)	(4,327)
Profit before income tax and social contribution	132,261	601,083	326,279	738,429
Current income tax and social contribution	46,010	(226)	(146,930)	(146,209)
Deferred income tax and social contribution	(60,980)	42,591	(44,661)	57,478
Net profit for the year	117,291	643,448	134,688	649,698
Result assigned for:				
Controlling shareholders	-	-	117,291	643,448
Non-controlling shareholders	-	-	17,397	6,250
Basic and diluted earnings per share				
Basic earnings per share	-	-	0.1186	0.6515
Diluted earnings per share	-	-	0.1186	0.6515

Explanatory notes are an integral part of the individual and consolidated financial statements.

EBITDA RECONCILIATION - CONSOLIDATED			
(In thousands of R\$)	2024	2023	Var %
Netincome	134,688	649,698	-79.3%
(+) Income Tax and Social Contribution	191,591	88,731	115.9%
(+) Net Financial Result	1,031,721	698,250	47.8%
(-) Depreciation and Amortization	499,656	320,399	55.9%
EBITDA	1,857,656	1,757,078	5.7%
EBITDA Margin	16.9%	19.3%	-2.3 p.p.
Adjusted EBITDA *	2,524,417	2,293,657	10.1%
Adjusted EBITDA Margin	23.0%	25.1%	-2.1 p.p.

* Adjusted for R&D expenses of R\$ 666,761 in 2024 and R\$ 536,579 in 2023

The financial statements are audited by KPMG Independent Auditors and full versions will be available on the website of Eurofarma Laboratórios S.A. Explanation notes are an integral part of the individual and consolidated financial statements. Carmelita Bittencourt da Silva Esteves-Accountant CRC SP 194171/O-5.